Surveillance active du cancer de prostate localisé

25 juin 2010

Auteurs : S.J. Drouin, M. Rouprêt, F. Hamdy, N. Mottet
Référence : Prog Urol, 2010, 20, S181, suppl. S3




 



Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser



Références



Boyle P., Severi G., Giles G.G. The epidemiology of prostate cancer Urol Clin North Am 2003 ;  30 : 209-217 [inter-ref]
Bryant R.J., Hamdy F.C. Screening for prostate cancer: an update Eur Urol 2008 ;  53 : 37-44 [cross-ref]
Schroder F.H., Carter H.B., Wolters T., van den Bergh R.C., Gosselaar C., Bangma C.H., et al. Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics Eur Urol 2008 ;  53 : 468-477 [cross-ref]
Albertsen P.C., Hanley J.A., Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer Jama 2005 ;  293 : 2095-2101 [cross-ref]
Penson D.F., McLerran D., Feng Z., Li L., Albertsen P.C., Gilliland F.D., et al. 5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study J Urol 2008 ;  179 (5Suppl) : S40-S44
Frankel S., Smith G.D., Donovan J., Neal D. Screening for prostate cancer Lancet 2003 ;  361 : 1122-1128 [cross-ref]
Johansson J.E., Andren O., Andersson S.O., Dickman P.W., Holmberg L., Magnuson A., et al. Natural history of early, localized prostate cancer Jama 2004 ;  291 : 2713-2719 [cross-ref]
Belot A., Grosclaude P., Bossard N., Jougla E., Benhamou E., Delafosse P., et al. Cancer incidence and mortality in France over the period 1980-2005 Rev Epidemiol Sante Publique 2008 ;  56 : 159-175 [inter-ref]
Bossard N., Velten M., Remontet L., Belot A., Maarouf N., Bouvier A.M., et al. Survival of cancer patients in France: a population-based study from The Association of the French Cancer Registries (FRANCIM) Eur J Cancer 2007 ;  43 : 149-160 [cross-ref]
Schroder F.H., Hugosson J., Roobol M.J., Tammela T.L., Ciatto S., Nelen V., et al. Screening and prostate-cancer mortality in a randomized European study N Engl J Med 2009 ;  360 : 1320-1328 [cross-ref]
Schroder F.H., Albertsen P. Open to debate. The motion: there is evidence that prostate cancer screening does more good than harm Eur Urol 2006 ;  50 : 377-380
Welch H.G., Schwartz L.M., Woloshin S. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal J Natl Cancer Inst 2005 ;  97 : 1132-1137 [cross-ref]
Miller D.C., Gruber S.B., Hollenbeck B.K., Montie J.E., Wei J.T. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States J Natl Cancer Inst 2006 ;  98 : 1134-1141 [cross-ref]
Bill-Axelson A., Holmberg L., Ruutu M., Haggman M., Andersson S.O., Bratell S., et al. Radical prostatectomy versus watchful waiting in early prostate cancer N Engl J Med 2005 ;  352 : 1977-1984 [cross-ref]
Warlick C., Trock B.J., Landis P., Epstein J.I., Carter H.B. Delayed versus immediate surgical intervention and prostate cancer outcome J Natl Cancer Inst 2006 ;  98 : 355-357 [cross-ref]
Kanso C., Etner J., Debre B., Zerbib M. Prostate cancer: medicoeconomic aspects Prog Urol 2010 ;  20 : 85-90 [cross-ref]
Choo R., DeBoer G., Klotz L., Danjoux C., Morton G.C., Rakovitch E., et al. PSA doubling time of prostate carcinoma managed with watchful observation alone Int J Radiat Oncol Biol Phys 2001 ;  50 : 615-620 [cross-ref]
Choo R., Klotz L., Danjoux C., Morton G.C., DeBoer G., Szumacher E., et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression J Urol 2002 ;  167 : 1664-1669 [cross-ref]
Dall’Era M.A., Cooperberg M.R., Chan J.M., Davies B.J., Albertsen P.C., Klotz L.H., et al. Active surveillance for early-stage prostate cancer: review of the current literature Cancer 2008 ;  112 : 1650-1659
Eggener S.E., Mueller A., Berglund R.K., Ayyathurai R., Soloway C., Soloway M.S., et al. A multi-institutional evaluation of active surveillance for low risk prostate cancer J Urol 2009 ;  181 : 1635-1641 [cross-ref]
Klotz L. Active surveillance for prostate cancer: for whom? J Clin Oncol 2005 ;  23 : 8165-8169 [cross-ref]
Hardie C., Parker C., Norman A., Eeles R., Horwich A., Huddart R., et al. Early outcomes of active surveillance for localized prostate cancer BJU international 2005 ;  95 : 956-960 [cross-ref]
Mottet N. Place de la surveillance active dans le cancer de la prostate : présentation du protocole français Prog Urol-FMC 2008 ;  18 : F12-F16 [inter-ref]
Klotz L., Nam R., Lam A., Mamedov A., Loblaw A. Clinical results of log term follow-up of a large active surveillance cohort  Chicago: AUA (2009). [Référence à compléter par l’auteur sur BAT].
Chun F.K., Haese A., Ahyai S.A., Walz J., Suardi N., Capitanio U., et al. Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men Cancer 2008 ;  113 : 701-709 [cross-ref]
Epstein J.I., Walsh P.C., Carmichael M., Brendler C.B. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer Jama 1994 ;  271 : 368-374 [cross-ref]
Bratt O. Watching the face of Janus - -active surveillance as a strategy to reduce overtreatment for localised prostate cancer Eur Urol 2006 ;  50 : 410-412 [cross-ref]
Suardi N., Capitanio U., Chun F.K., Graefen M., Perrotte P., Schlomm T., et al. Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features Cancer 2008 ;  113 : 2068-2072 [cross-ref]
Berglund R.K., Masterson T.A., Vora K.C., Eggener S.E., Eastham J.A., Guillonneau B.D. Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance J Urol 2008 ;  180 : 1964-1967 [cross-ref]
Al Otaibi M., Ross P., Fahmy N., Jeyaganth S., Trottier H., Sircar K., et al. Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance Cancer 2008 ;  113 : 286-292 [cross-ref]
Klotz L. Active surveillance with selective delayed intervention for favorable risk prostate cancer Urol Oncol 2006 ;  24 : 46-50 [cross-ref]
Carter H.B., Ferrucci L., Kettermann A., Landis P., Wright E.J., Epstein J.I., et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability J Natl Cancer Inst 2006 ;  98 : 1521-1527 [cross-ref]
van As N.J., Norman A.R., Thomas K., Khoo V.S., Thompson A., Huddart R.A., et al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance Eur Urol 2008 ;  54 : 1297-1305 [cross-ref]






© 2010 
Elsevier Masson SAS. Tous droits réservés.